Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
New Glucose Sensor Pediatric
An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects
Status: Archived
Sutter Institute for Medical Research
mi
from
Sacramento, CA
New Glucose Sensor Pediatric
An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects
Status: Archived
Updated: 1/1/1970
Sutter Institute for Medical Research
mi
from
Sacramento, CA
New Glucose Sensor Pediatric
An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects
Status: Archived
Endocrinology/ University of South Florida
mi
from
St. Petersburg, FL
New Glucose Sensor Pediatric
An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects
Status: Archived
Updated: 1/1/1970
Endocrinology/ University of South Florida
mi
from
St. Petersburg, FL
New Glucose Sensor Pediatric
An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
New Glucose Sensor Pediatric
An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.25.10035 Boehringer Ingelheim Investigational Site
mi
from
Anaheim, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.25.10035 Boehringer Ingelheim Investigational Site
mi
from
Anaheim, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01339 Boehringer Ingelheim Investigational Site
mi
from
Lomita, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01339 Boehringer Ingelheim Investigational Site
mi
from
Lomita, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10009 Boehringer Ingelheim Investigational Site
mi
from
West Palm Beach, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10009 Boehringer Ingelheim Investigational Site
mi
from
West Palm Beach, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.61.01038 Boehringer Ingelheim Investigational Site
mi
from
Honolulu, HI
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.61.01038 Boehringer Ingelheim Investigational Site
mi
from
Honolulu, HI
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01091 Boehringer Ingelheim Investigational Site
mi
from
Shreveport, LA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01091 Boehringer Ingelheim Investigational Site
mi
from
Shreveport, LA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10010 Boehringer Ingelheim Investigational Site
mi
from
Billerica, MA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10010 Boehringer Ingelheim Investigational Site
mi
from
Billerica, MA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01014 Boehringer Ingelheim Investigational Site
mi
from
Chesterfield, MO
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01014 Boehringer Ingelheim Investigational Site
mi
from
Chesterfield, MO
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01142 Boehringer Ingelheim Investigational Site
mi
from
Endwell, NY
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01142 Boehringer Ingelheim Investigational Site
mi
from
Endwell, NY
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.25.10010 Boehringer Ingelheim Investigational Site
mi
from
Greenville, NC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.25.10010 Boehringer Ingelheim Investigational Site
mi
from
Greenville, NC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10005 Boehringer Ingelheim Investigational Site
mi
from
Bethlehem, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10005 Boehringer Ingelheim Investigational Site
mi
from
Bethlehem, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01093 Boehringer Ingelheim Investigational Site
mi
from
Greer, SC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01093 Boehringer Ingelheim Investigational Site
mi
from
Greer, SC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1200.32.2609 Boehringer Ingelheim Investigational Site
mi
from
Corpus Christi, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1200.32.2609 Boehringer Ingelheim Investigational Site
mi
from
Corpus Christi, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10023 Boehringer Ingelheim Investigational Site
mi
from
Renton, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10023 Boehringer Ingelheim Investigational Site
mi
from
Renton, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Birmingham, AL
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Birmingham, AL
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Peoria, AZ
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Peoria, AZ
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Long Beach, CA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Long Beach, CA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Washington,
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Washington,
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
North Dartmouth, MA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
North Dartmouth, MA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Minneapolis, MN
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Minneapolis, MN
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Las Vegas, NV
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Las Vegas, NV
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Newark, NJ
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Newark, NJ
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
New York, NY
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
New York, NY
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
St. Luke Whiteside Research
mi
from
Duluth, MN
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
St. Luke Whiteside Research
mi
from
Duluth, MN
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Philadelphia, PA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Philadelphia, PA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Charleston, SC
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Charleston, SC
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Fort Worth, TX
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Fort Worth, TX
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Salt Lake City, UT
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Salt Lake City, UT
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, VA
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, VA
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
205.452.01317 Boehringer Ingelheim Investigational Site
mi
from
Mesa, AZ
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
205.452.01317 Boehringer Ingelheim Investigational Site
mi
from
Mesa, AZ
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.28.10016 Boehringer Ingelheim Investigational Site
mi
from
Hot Springs, AR
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.28.10016 Boehringer Ingelheim Investigational Site
mi
from
Hot Springs, AR
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10154 Boehringer Ingelheim Investigational Site
mi
from
Chino, CA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10154 Boehringer Ingelheim Investigational Site
mi
from
Chino, CA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10009 Boehringer Ingelheim Investigational Site
mi
from
Santa Ana, CA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10009 Boehringer Ingelheim Investigational Site
mi
from
Santa Ana, CA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.28.10021 Boehringer Ingelheim Investigational Site
mi
from
West Hills, CA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.28.10021 Boehringer Ingelheim Investigational Site
mi
from
West Hills, CA